Idenix rally may be linked to AASLD meeting: Deutsche

|About: Idenix Pharmaceuticals, Inc. (IDIX)|By:, SA News Editor

Deutsche's Alethia Young thinks the rally in shares of Idenix Pharmaceuticals (IDIX +41%) may be attributable to the upcoming AASLD meeting which begins this weekend.

Here's Young: "IDIX has noted that they are not interested in an exclusive arrangement with JNJ or anyone else [but] we would assume that any HCV developer would be interested in a nuke."

IDIX's HELIX-1 trial is evaluating the company's NS5A inhibitor, samatasvirin in combination with JNJ's simeprevir.

Deutsche has the shares at Hold.